Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous mesenchymal stem cells (Mayo Clinic)
- Development stage
- Unknown
- Lead developer
- Mayo Clinic
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
Autologous Mesenchymal Stem Cells is a cell-based regenerative therapy being developed by Mayo Clinic for the treatment of multiple system atrophy (MSA). The therapy involves harvesting mesenchymal stem cells (MSCs) from a patient's own adipose tissue, expanding them in vitro, and then delivering them back to the patient via intrathecal injection. The mechanism of action is centered on the paracrine secretion of neurotrophic factors by the MSCs, which is intended to provide neuroprotective support and potentially slow the progression of the neurodegenerative processes characteristic of MSA, such as autonomic failure, parkinsonism, and ataxia. Clinical data from early-phase trials have demonstrated safety and tolerability, with signals of dose-dependent efficacy in reducing disease progression compared to historical controls.
- Other names
- adipose-derived autologous mesenchymal stem cellsautologous MSCs
Beyond the preview
Go deeper on autologous mesenchymal stem cells (Mayo Clinic).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous mesenchymal stem cells (Mayo Clinic).